Business magnate Li Ka-shing makes a personal appearance for the first time since closing the deal on Hutchison ports.
A Game-Changer for Liver Cancer Patients: Li Ka-shing's generosity brings advanced treatment to HKSH
The recent delivery of the "Histotripsy 2.0" system to the Hong Kong Sanatorium & Hospital (HKSH) is causing quite a stir. This non-invasive device, which uses ultrasound waves to destroy tumors, provides a much-needed precision treatment option for liver cancer patients.
The 96-year-old tycoon, Li Ka-shing, known as the "Superman" of business, was all smiles as he met Walton Li Wai-tat, the CEO of HKSH Medical Group and the hospital's medical superintendent. Li made a rare appearance, expressing his excitement about this revolutionary development in healthcare.
TheFoundation—a key supporter behind this advancement—played a crucial role in making this a reality. Not only did they donate the Histotripsy 2.0 system, but their donation aligns with their longstanding commitmentto advancing oncology research. In fact, they've been at the forefront of supporting precision medicine initiatives, as demonstrated by their 2017 $3 million grant to the University of Melbourne Centre for Cancer Research.
The Histotripsy 2.0 system delivers on Li's broader philanthropic strategy: he's targeting high-impact medical advancements, particularly in areas like precision oncology and non-invasive therapies. The adoption of this innovative technology is just one example of how Li's funding accelerates change, transforming cancer care in Asia as highlighted in the 2025 sustainability report of CK Hutchison.
It's fantastic news for those battling liver cancer, and we can only hope that this marks the beginning of even greater strides in medical advancement. Let's celebrate Li's generosity and the promise it holds for the future of healthcare!
- Li Ka-shing's donation of the Histotripsy 2.0 system to the Hong Kong Sanatorium & Hospital (HKSH) is a significant addition to the trade of medical-condition treatments, as it provides a precise, non-invasive solution for liver cancer patients.
- The tycoon's generous donation represents a fusion of science and business, furthering his reputation as a superman in the realm of finance and health-and-wellness.
- The rare appearance of Li Ka-shing at the HKSH Medical Group was a testament to his interest and commitment to the trade of precision oncology, particularly in the use of advanced ultrasound technology.
- The Foundation's support of the Histotripsy 2.0 system demonstrates their long-term focus on finance and business, with a special emphasis on backing rare initiatives that significantly impact science-based medical conditions such as cancer.
- The adoption of the Histotripsy 2.0 system is a game-changer for not only HKSH, but also the broader business landscape, as it aligns with Li Ka-shing's strategy of investing in health-and-wellness innovations.
- The promise that Li Ka-shing's generosity holds for future healthcare advancements extends beyond Hong Kong, potentially revolutionizing the trade of liver cancer treatments across Asia and the world.
